Dociparstat Sodium is a polysaccharide commercialized by Chimerix, with a leading Phase III program in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to Globaldata, it is involved in 11 clinical trials, of which 6 were completed, 1 is ongoing, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Dociparstat Sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Dociparstat Sodium is expected to reach an annual total of $214 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Dociparstat Sodium Overview
Dociparstat sodium (CX-01, PGX-100, ODSH) is under development for the treatment of acute myeloid leukemia and traumatic brain injury. The drug candidate is a multi-targeted new chemical entity (NCE). It is administered intravenously and subcutaneously as a solution. The drug candidate targets neutrophil elastases and CXCL12.
It was also under development for treatment chronic obstructive pulmonary disease (COPD), reperfusion injury, acute myocardial infarction (AMI), age-related macular degeneration, gastrointestinal disorder, autologous, refractory acute myeloid leukemia, myelodysplastic syndrome, allogenic bone marrow transplantation rejection, metastatic pancreatic cancer, radiation toxicity, graft versus host disease (GVHD), solid tumors, non-small cell lung cancer, chemotherapy-induced thrombocytopenia, small cell lung cancer and COVID-19 patients with acute lung injury (ALI).
Chimerix is a biopharmaceutical company. It develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s pipeline product portfolio includes ONC201, ONC206, ONC212, CMX521 drug candidates. Its products are used to treat various diseases like gliomas, central nervous system tumors, SARS-CoV-2 (COVID-19), and IND-enabling studies. Its brincidofovir tablet and oral suspension formulations are used in the treatment of smallpox disease in adult and pediatric patients. The company markets its products under the brand name of TEMBEXA. The organization works in partnership with Oncoceutics, Inc., Cantex Pharmaceuticals, BARDA, and SymBio Pharmaceuticals. Chimerix is headquartered in Durham, North Carolina, the US.
The company reported revenues of (US Dollars) US$2 million for the fiscal year ended December 2021 (FY2021), a decrease of 63.2% over FY2020. The operating loss of the company was US$173.4 million in FY2021, compared to an operating loss of US$44.5 million in FY2020. The net loss of the company was US$173.2 million in FY2021, compared to a net loss of US$43.5 million in FY2020. The company reported revenues of US$32.6 million for the third quarter ended September 2022, compared to a revenue of US$0.4 million the previous quarter.
For a complete picture of Dociparstat Sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.